论文部分内容阅读
避孕药具安全性是关系到使用者健康权益的重大问题,得到中国政府的高度重视。多年来,在国家科技项目和省部共建“国家人口和计划生育委员会计划生育药具不良反应监测中心”的推进下,建立既符合国际标准,又适宜中国国情的避孕药具上市后安全性监测模式、技术规范和风险评价体系。目前,全国31个省市已建立105个避孕药具不良反应监测试点,实现主动监测与自愿报告的记录联接,进行不同类型避孕药具不良反应/不良事件发生率的排序,为避孕药具荐优汰劣、避孕方法知情选择和优质服务提供科学依据,促进避孕安全和人口安全。
The safety of contraceptives is a major issue that affects the health and safety of users. It is highly regarded by the Chinese government. Over the years, the state science and technology projects and the provincial government to jointly build the “National Population and Family Planning Commission family planning adverse drug reaction monitoring center” to promote the establishment of both contraceptives that meet international standards, but also suitable for China’s national conditions after the listing Security monitoring model, technical specifications and risk assessment system. Currently, 31 provinces and cities nationwide have established 105 pilot stations for the monitoring of adverse drug reactions, and achieved the record connection between active monitoring and voluntary reporting, and sorted the incidence of adverse reactions / adverse events of different types of contraceptives for the contraceptives Out of the poor, the informed choice of contraceptive methods and quality services to provide a scientific basis to promote contraception and population safety.